Narendra Modi reviews COVID-19 vaccine development efforts in Ahmedabad, Hyderabad, and Pune

-

Ahmedabad/Hyderabad/Pune: Prime Minister Narendra Modi on Saturday visited Ahmedabad, Hyderabad and Pune to review coronavirus vaccine development work there. The Prime Minister's Office said the day-long visit was aimed at getting a first-hand perspective of the preparations, challenges and road map in India's endeavour to vaccinate its citizens.

Modi began by visiting pharma major Zydus Cadila's manufacturing facility near Ahmedabad. Wearing a PPE kit, he reviewed the vaccine development process at the company's research centre, located over 20 kilometres from Ahmedabad.

Modi was extensively briefed about the vaccine work at the plant by the company officials. He was briefed about the vaccine production procedure. He interacted with scientists and vaccine developers, an official said.

"Visited the Zydus Biotech Park in Ahmedabad to know more about the indigenous DNA based vaccine being developed by Zydus Cadila. I compliment the team behind this effort for their work. Government of India is actively working with them to support them in this journey," Modi tweeted after the visit.

Zydus Cadila chairman Pankaj Patel recently said the company is aiming to complete the vaccine trial by March 2021, and could produce up to 100 million doses a year.

Modi, who landed at Ahmedabad at 9.10 am, spent over an hour at the plant, before leaving for the airport, from where he left for Hyderabad at 11.40 am.

Modi landed at Hakimpet Air Force station near Hyderabad around 1 pm and proceeded to pharma major Bharat Biotech's vaccine manufacturing facility at Genome valley, located around 20 km from the air station, by road.

At the facility, he reviewed the progress of Covaxin, a vaccine candidate being developed by the company. He also interacted with Bharat Biotech Chairman and Managing Director Krishna Ella, scientists and senior management.

"At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress," Modi tweeted after his hour-long visit there.

After leaving the facility, Modi got down from his vehicle at the main gate and waved to media persons and the cheering crowd standing nearby.

Covaxin, being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology, is undergoing phase-3 trials.

At 3.20 pm, Modi took off for Pune, where he landed at 4.30 pm on the last leg of his three-city vaccine work review visit. Modi then proceeded by helicopter to the campus of the Serum Institute of India (SII) at Manjari, located 17 km from the airport.

At the Serum Institute of India, Modi reviewed the progress of the 'Covishield' vaccine being made there. Modi interacted with scientists at the Serum Institute and had a walkabout of the facility, taking stock of vaccine development work being carried out there.

At the facility, Modi was received by Dr Cyrus Poonawalla, chairman of Poonwalla Group, and his son and SII CEO Adar Poonawalla. They briefed Modi about the work being carried out at SII.

Modi interacted with the Poonawallas, scientists and other executives, who briefed him on the vaccine's progress.

"Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility," Modi tweeted after his SII visit.

Serum Institute of India has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine.

Modi left from SII for Pune airport around 6 pm and took off for Delhi at 6.25 pm, an official said.



from Firstpost India Latest News https://ift.tt/3q94khL
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

120 flights delayed, 30 trains running late; Delhi fog & cold wave continue to give shiver to travellers

-
Arrival and departure of 120 flights, both domestic and international, to Delhi airport were affected due to dense fog and cold wave conditions on Wednesday, according to Delhi Airport FIDS (Flight Information Display System). As per the Delhi Airport FIDS, a total of 53 flights, including 21 domestic arrivals, 16 domestic departures, 13 international departures and three international arrivals scheduled are cancelled and not operating due to fog and other operational reasons from and to Indira Gandhi International (IGI) Airport in the national capital on 17 January. #WATCH | Delhi: Several flight operations delayed at IGI airport due to low visibility amid fog. pic.twitter.com/hG1DUKllEt — ANI (@ANI) January 17, 2024 Visuals from the Delhi airport showed passengers waiting outside, checking update of their scheduled flights. There were also some people waiting for flight of their families, friends and loved ones to arrive, which got delayed due to fog. #WATCH | Delhi | Pas
Read more